Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
TAK-012 by Takeda Pharmaceutical for Refractory Acute Myeloid Leukemia: Likelihood of Approval
TAK-012 is under clinical development by Takeda Pharmaceutical and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...
Data Insights
TAK-012 by Takeda Pharmaceutical for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
TAK-012 is under clinical development by Takeda Pharmaceutical and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...